Carmignac Gestion’s Gilead Sciences GILD Stock Holding History

Carmignac Gestion’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,000	Closed	-$123K	–	140
2022 Q3	$123K	Buy	+2,000	New	+$126K	﹤0.01%	119

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Carmignac Gestion's GILD Position: Q4 2022 in Review

Carmignac Gestion sold out of Gilead Sciences (GILD) in Q4 2022, closing a stake of 2,000 shares — an estimated $123K sold.

Carmignac Gestion first reported a position in GILD in Q3 2022 and held it in 1 quarter. The position peaked at $123K in Q3 2022. 1,767 funds tracked by Wall St. Rank hold GILD as of Q4 2022.

Carmignac Gestion reported no remaining Gilead Sciences position as of Q4 2022 after selling out during the quarter.
Carmignac Gestion sold 2,000 Gilead Sciences shares in Q4 2022, an estimated $123K.
Carmignac Gestion first reported a position in Gilead Sciences in Q3 2022 and held it in 1 quarter.
Carmignac Gestion's Gilead Sciences position peaked at $123K in Q3 2022.
1,767 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2022.

Based on Carmignac Gestion's 13F filing for Q4 2022, filed 13 Feb 2023.